Comparison of fixed dose (6 MG) pegfilgrastim and daily filgrastim to accelerate hemopoietic recovery after autologous stem cell transplantation (ASCT)

被引：0
|
作者：
Marcacci, G
Petti, MC
Ferrara, F
Scarpato, N
Storti, S
D'Arena, G
Palombi, F
Palmieri, S
Andretta, C
Pinto, A
机构：
[1] IRCCS, Fdz Pascale, Hematol Oncol & Bone Marrow Transplantat Unit, NCI, Naples, Italy
[2] Regina Elena IRCCS, Hematol Unit, NCI, Rome, Italy
[3] AORN Cardarelli, Hematol & BNT Unit, Naples, Italy
[4] AOU Federico 2, Hamephereis Unit, Naples, Italy
[5] Catholic Univ, Hematol Oncol Unit, Campobasso, Italy
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2006年 / 12卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2005.11.288
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
265
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [41] Efficacy of single-dose pegfilgrastim compared with daily filgrastim to mobilize autologous peripheral blood stem cells after chemotherapy in malignant lymphomas
    Bassi, S.
    Nassi, L.
    Massaro, C.
    Gigli, F.
    Quarna, J.
    Bertazzoni, P.
    Saronni, L.
    Babic, A.
    Sammassimo, S.
    Cascio, R.
    Orlando, L.
    Rafaniello, P.
    Martinelli, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 241
  • [42] Cell dose and hematologic recovery after autologous stem cell transplantation for multiple myeloma
    Tonev, Ivan
    Simeonov, Stanislav
    Ilieva, Marina
    Mitkoff, Ivan
    Arnaudov, Georgi
    Ganeva, Penka
    Petrov, Yavor
    Spassov, Branimir
    Mincheff, Milcho
    BONE MARROW TRANSPLANTATION, 2019, 54 : 509 - 510
  • [43] Lenograstim and filgrastim are equally effective for the hematopoeitic recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation
    Teschendorf, C.
    Karaivanova, D.
    Koldehoff, M.
    Schmiegel, W.
    Graeven, U.
    ONKOLOGIE, 2010, 33 : 140 - 140
  • [44] Effects of lenograstim or filgrastim on blood cell recovery after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplantation (PBSCT)
    Bojko, Peter
    Huettmann, Andreas
    Schirsafi, Kasra
    Seeber, Siegfried
    ANNALS OF ONCOLOGY, 2004, 15 : 223 - 223
  • [45] Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: An economic evaluation of the PALM trial
    Perrier L.
    Lefranc A.
    Pérol D.
    Quittet P.
    Schmidt-Tanguy A.
    Siani C.
    De Peretti C.
    Favier B.
    Biron P.
    Moreau P.
    Bay J.O.
    Lissandre S.
    Jardin F.
    Espinouse D.
    Sebban C.
    Applied Health Economics and Health Policy, 2013, 11 (2) : 129 - 138
  • [46] Autologous stem cell transplantation (ASCT) in lymphomas:: impact of previous chemotherapy and CD34+cell dose on hematological recovery
    Martin, A
    Pérez-Simón, JA
    Caballero, MD
    López, N
    Vázquez, L
    Cañizo, MC
    García-Sanz, R
    San Miguel, JF
    BONE MARROW TRANSPLANTATION, 2002, 29 : S95 - S95
  • [47] COST-EFFECTIVENESS OF EARLY VERSUS LATE FILGRASTIM ADMINISTRATION IN AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)
    Salazar, M. J. Rodriguez
    Hernandez-Garcia, M. T.
    Gonzalez-Gonzalez, B. J.
    Raya, J. M.
    Rodriguez-Sanchez, R. F.
    Gonzalez-Brito, G.
    Martin, T.
    Morabito, L.
    Hernandez-Nieto, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 427 - 427
  • [48] A non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in paediatric patients after autologous peripheral blood stem cell transplant
    Cesaro, S.
    Nesi, F.
    Tridello, G.
    Fagioli, F.
    Abate, M.
    Panizzolo, I.
    Rondelli, R.
    Calore, E.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S372 - S372
  • [49] Dendritic cell recovery after autologous stem cell transplantation
    D Damiani
    R Stocchi
    P Masolini
    A Michelutti
    A Sperotto
    A Geromin
    C Skert
    M Cerno
    M Michieli
    M Baccarani
    R Fanin
    Bone Marrow Transplantation, 2002, 30 : 261 - 266
  • [50] Pegfilgrastim shows safety and efficacy similar to filgrastim in patients undergoing autologous stem cell transplantation for hematological malignancies.
    Neumeister, P
    Holub, R
    Staber, PB
    Linkesch, W
    BLOOD, 2004, 104 (11) : 327A - 327A
12345